= Add Download to Briefcase

Corporate

Title	Date	Type	Size
May 2012 Corporate Presentation	May 10, 2012		1.2 MB

To request for additional information on Presentations and Articles, please click here.

Scientific

Title	Date	Type	Size
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study	Dec 13, 2011		1.1 MB
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial	Dec 12, 2011		787.2 KB
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL	Dec 12, 2011		1.4 MB

To request for additional information on Presentations and Articles, please click here.